There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Altimmune (ALT – Research Report) and Nuwellis (NUWE – Research Report) with bullish sentiments.
Altimmune (ALT)
In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Altimmune, with a price target of $15.00. The company’s shares closed last Wednesday at $4.98, close to its 52-week low of $3.82.
According to TipRanks.com, Wolleben is a 4-star analyst with an average return of
Altimmune has an analyst consensus of Strong Buy, with a price target consensus of $26.17.
See Insiders’ Hot Stocks on TipRanks >>
Nuwellis (NUWE)
Maxim Group analyst Anthony Vendetti maintained a Buy rating on Nuwellis yesterday. The company’s shares closed last Wednesday at $3.15.
According to TipRanks.com, Vendetti is a 1-star analyst with an average return of
Nuwellis has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALT:
- Altimmune to Participate at Two Upcoming Investor Conferences
- Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
- Altimmune call volume above normal and directionally bullish
- Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell™, an Immunotherapeutic for Chronic Hepatitis B
- Altimmune completes enrollment in Phase 2 trial of HepTcell
